FluidForm

FluidForm Bio is a biotechnology company focused on developing lifelike human tissues for disease treatment and drug discovery applications. Their patented FRESH 3D bioprinting technology enables the recreation of complex biological structures with high precision and fidelity. FluidForm's approach involves printing cells, proteins, and extracellular matrices in their native, unmodified forms to create tissue constructs that closely mimic the structure and function of real human tissues.

The FRESH platform overcomes limitations of traditional tissue engineering methods by enabling high cell densities and uniaxial alignment, resulting in advanced physiological function. This technology has been successfully used to bioprint components of the human heart, including small blood vessels, valves, and beating ventricles. FluidForm has demonstrated the ability to build the most lifelike engineered tissues to date.

In addition to tissue therapeutics, FluidForm aims to develop complex tissue models for drug testing and toxicity studies. Traditional 2D cell cultures often fail to accurately predict drug responses, and FluidForm's 3D bioprinted tissues could provide a more predictive platform for pharmaceutical research. The company has partnered with several major life science companies, such as Merck & Co. and Ethicon (Johnson & Johnson), to validate and advance their technology.